SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-051634
Filing Date
2024-04-25
Accepted
2024-04-25 08:00:40
Documents
19
Period of Report
2024-06-13

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm242684d2_def14a.htm   iXBRL DEF 14A 1305091
6 GRAPHIC bc_paidvsnetloss-4c.jpg GRAPHIC 67456
7 GRAPHIC bc_paidvstsr-4c.jpg GRAPHIC 70129
8 GRAPHIC bc_paidvsyearendcash-4c.jpg GRAPHIC 72601
9 GRAPHIC px_24celldexproxy1pg01-bw.jpg GRAPHIC 252490
10 GRAPHIC px_24celldexproxy1pg02-4c.jpg GRAPHIC 151678
  Complete submission text file 0001104659-24-051634.txt   3599893

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cldx-20231231.xsd EX-101.SCH 9255
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cldx-20231231_def.xml EX-101.DEF 5839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cldx-20231231_lab.xml EX-101.LAB 30694
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cldx-20231231_pre.xml EX-101.PRE 4755
22 EXTRACTED XBRL INSTANCE DOCUMENT tm242684d2_def14a_htm.xml XML 204372
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-15006 | Film No.: 24873064
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)